盐酸螺哌隆  ≥98%

促销价¥{{model.attbuying.price}}

市场价¥0.00

累计销量0 累计评价0 人评论

别称 {{model.alias}}
中文名称 {{model.name}}
英文名称 {{model.enname}}
品牌 {{model.brand}}
CAS {{model.cas}}
分子式
分子量 {{model.molecularweight}}
MDL {{model.mdl}}
货号 {{model.procode}}
数量

+ -

库存{{model.attbuying.number}}
包装规格:5mg 10mg 100mg in glass bottle
产品描述:基本信息 产品编号: S10817 产品名称: Spiperone hydrochloride CAS: 2022-29-9   储存条件 粉末 -20℃ 四年     分子式: C23H27ClFN3O2 溶于液体 -80℃ 6个月 分子量: 431.93 -20℃ 1个月 化学名:  8-[4-(4-fluorophenyl)-4-oxobutyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one;hydrochloride Solubility (25°C):   体外:   DMSO   Ethanol   Water   体内(现配现用):   <1mg/ml表示微溶或不溶。 普西唐提供的所有化合物浓度为内部测试所得,实际溶液度可能与公布值有所偏差,属于正常的批间细微差异现象。 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;⼀旦配成溶液,请分装保存,避免反复冻融造成的产品失效。   制备储备液   浓度   溶液体积 质量   1mg   5mg   10mg 1mM 2.3152mL 11.5759mL 23.1519mL 5mM 0.4630mL 2.3152mL 4.6304mL 10mM 0.2315mL 1.1576mL 2.3152mL   生物活性 产品描述 一种选择性的多巴胺 D2 受体 (D2,D3,D4,D1 和 D5 受体的 Ki 值分别为 0.06nM,0.6nM,0.08nM,~350nM,~3500nM) 和 5-HT2A/5-HT1A 受体 (Ki 为1nM/49nM) 拮抗剂。Spiperone hydrochloride 也是一种选择性的 α1B-肾上腺素受体 (α1B-adrenoceptor) 拮抗剂。Spiperone hydrochloride 激活钙激活的氯离子通道 (CaCC)。抗精神病和抗炎作用。 靶点 Dopamine Receptor 5-HT Receptor Adrenergic Receptor Chloride Channel   体外研究 Spiperone is a potent intracellular Ca2+ enhancer (EC50=9.3μM) and stimulates intracellular Ca2+through a protein tyrosine kinase-coupled phospholipase C-dependent pathway,which results in increased secretion of Cl-in Calu-3 and CFBE41o-cell monolayers.Spiperone significantly decreases the production of nitric oxide in lipopolysaccharide-stimulated BV-2 microglia cells,primary microglia and primary astrocyte cultures.Spiperone also significantly inhibits nitric oxide production in ATPstimulated primary microglia cultures.Spiperone markedly decreases the production of TNF-α in BV-2 microglia cells.Spiperone attenuates the expression of inducible nitric oxide synthase and proinflammatory cytokines such as IL-1β and TNF-α at mRNA levels in BV-2 microglia cells. 体内研究 Spiperone (1.5mg/kg;intraperitoneal injection;on days 1,3,6,7,and 13-21;C57Bl/6 mice) treatment reduces infiltration of the alveolar interstitium and alveolar ducts with inflammatory cells and prevents the growth of the connective tissue in the parenchyma of Bleomycin lungs. Animal Model: C57Bl/6 mice (7-8-week-old) induced pulmonary fibrosis by Bleomycin Dosage: 1.5mg/kg Administration: Intraperitoneal injection;on days 1,3,6,7,and 13-21 Result: Reduced infiltration of the alveolar interstitium and alveolar ducts with inflammatory cells and prevented the growth of the connective tissue in the parenchyma of bleomycin lungs.
保存条件:-20℃